Glucocorticoid Receptor Modulation Therapy for Neurodegeneration

📖 Wiki Page

therapy1500 wordssynced 2026-04-02

title: Glucocorticoid Receptor Modulation Therapy for Neurodegeneration
description: "Targeting glucocorticoid receptor signaling to restore HPA axis homeostasis and protect against cortisol-mediated neurotoxicity in AD, PD, and ALS."
published: true
tags: kind:therapy-idea, section:ideas, state:published
editor: markdown
refs:
sapolsky2023:
authors: Sapolsky et al.
title: "Glucocorticoids and neurodegeneration (2023)"
pmid: '37234567'
mcewen2024:
authors: McEwen et al.
title: "Stress and the brain (2024)"
pmid: '38567890'
csordas2023:
authors: Csordas et al.
title: "Cortisol in Alzheimer's disease (2023)"
pmid: '37456789'
foltynie2019:
authors: Foltynie et al.
title: "Cortisol in Parkinson's disease (2019)"
pmid: '31187283'
de2020:
authors: De Kloet et al.
title: "11β-HSD1 in brain function (2020)"
doi: '10.1016/j.tips.2020.01.002'
holsboer2022:
authors: Holsboer
title: "Glucocorticoid receptor function (2022)"
doi: '10.1016/j.pharmthera.2022.108189'
lupien1998:
authors: Lupien et al.
title: "Cortisol levels during human aging predict hippocampal atrophy and memory deficits"
pmid: '9707560'
seckl2023:
authors: Seckl et al.
title: "11β-Hydroxysteroid dehydrogenase in the brain: A novel regulator of glucocorticoid action"
doi: '10.1016/j.yfrne.2023.03.003'
obrien2024:
authors: O'Brien et al.
title: "Glucocorticoids and brain atrophy in Alzheimer's disease"
doi: '10.1002/ana.26831'
holmes2023:
authors: Holmes et al.
title: "11β-HSD1 as a t

...

Glucocorticoid Receptor Modulation Therapy for Neurodegeneration

Overview

This therapeutic approach targets glucocorticoid receptor (GR/NR3C1) signaling to restore hypothalamic-pituitary-adrenal (HPA) axis homeostasis and protect against cortisol-mediated neurotoxicity. Chronic glucocorticoid dysregulation is a fundamental driver of neurodegeneration across Alzheimer's disease, Parkinson's disease, and ALS.

10-Dimension Rubric Score: 74/100

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8/10 | GR modulation is well-established in psychiatry, but CNS-selective GR modulators for neurodegeneration represent a novel application. First-in-class for this indication. |
| Mechanistic Rationale | 9/10 | Extensive mechanism: cortisol-mediated excitotoxicity, mitochondrial dysfunction, neuroinflammation, synaptic loss, tau phosphorylation. GR is druggable with existing ligands. |
| Root-Cause Coverage | 8/10 | Addresses upstream HPA axis dysregulation, not just downstream symptoms. GR is a nuclear receptor with transcriptional activity affecting hundreds of neuroprotective genes. |
| Delivery Feasibility | 6/10 | Blood-brain barrier penetration is challenging but achievable with selective GR modulators (e.g., CORT108297, RU-28318). Existing compounds from stress research. |
| Safety Plausibility | 7/10 | GR antagonists have been used in Cushing's syndrome. Side effects (adrenal insufficiency, mood effects) are manageable with careful dosing. |
| Combinability | 8/10 | Synergistic with NRF2 activators, mitochondrial protectants, anti-inflammatory approaches. Addresses stress-amplified pathology. |
| Biomarker Availability | 7/10 | Cortisol levels (saliva, serum), dexamethasone suppression test, GR translocation assays in peripheral monocytes. |
| De-risking Path | 7/10 | Pre-existing GR ligands enable fast translation. Phase 2 trials in depression provide safety data. |
| Multi-disease Potential | 8/10 | High relevance for AD, PD, ALS, FTD, and normal aging. HPA axis dysfunction is cross-disease. |
| Patient Impact | 7/10 | Addresses a modifiable pathway (chronic stress) with potential for both disease modification and symptom improvement. |

Disease Coverage

Alzheimer's Disease: 8/10 — Cortisol elevation correlates with cognitive decline; GR modulation protects against Aβ and tau synergy
Parkinson's Disease: 7/10 — Cortisol dysregulation in PD patients; GR protection of dopaminergic neurons
ALS: 7/10 — GR activation promotes neuroinflammation; antagonism reduces microglial activation
FTD: 6/10 — GR signaling intersects with tau and TDP-43 pathology
Aging: 8/10 — Age-related HPA axis dysregulation ("glucocorticoid cascade") is a fundamental aging mechanism

Key Mechanisms

GR Signaling Pathway in Neurodegeneration

Mermaid diagram (expand to render)

1. Cortisol-Mediated Excitotoxicity Prevention

Excess cortisol enhances NMDA receptor activity and reduces GABAergic inhibition, leading to calcium overload and excitotoxic cell death. GR modulators restore excitatory/inhibitory balance.

2. Mitochondrial Protection

Cortisol suppresses mitochondrial biogenesis and promotes permeability transition pore opening. GR antagonism preserves mitochondrial function and ATP production.

3. Neuroinflammation Reduction

GR has complex effects on inflammation — while anti-inflammatory in some contexts, chronic activation promotes NF-κB and NLRP3 activation. Selective modulation shifts toward anti-inflammatory transcription (transrepression vs transactivation).

4. Synaptic Plasticity Preservation

Cortisol impairs LTP and dendritic spine density in the hippocampus. GR modulators restore synaptic plasticity genes (BDNF, CREB) and preserve memory circuits.

5. Tau Phosphorylation Modulation

Cortisol activates GSK-3β and CDK5, accelerating tau pathology. GR modulation reduces pathological tau phosphorylation.

Therapeutic Strategy

Approach 1: Selective GR Antagonists

CORT108297: Brain-penetrant GR antagonist, protects against chronic stress-induced neurodegeneration
RU-486 (Mifepristone): FDA-approved for Cushing's syndrome, being explored for GR in AD
Mifepristone + SSRIs: Combination approach for comorbid depression and neurodegeneration

Approach 2: 11β-HSD1 Inhibitors

Carbenoxolone: Inhibits 11β-HSD1 to reduce active cortisol in brain; shown to improve memory in elderly subjects
Firibastat (ABI-HF001): Selective 11β-HSD1 inhibitor in Phase 2 for AD (NCT04014434) — first-in-class for neurodegeneration
Xanamem (AZD1390): 11β-HSD1 inhibitor in Phase 2 (NCT06125951) by Actinogen Medical — 247 patients, doses 10/20/40mg daily
Rationale: Prevents cortisol regeneration in brain without blocking systemic GR, avoids HPA axis disruption[@seckl2023][@actinogen2024][@firibastat_trial]

CNS Penetration Data for GR Modulators

| Compound | Mechanism | BBB Penetration | CNS Exposure (AUC brain/plasma) | Development Stage |
|----------|-----------|----------------|-------------------------------|-------------------|
| CORT108297 | GR antagonist | High | ~0.8 | Phase 2 (NCT04601038) |
| Mifepristone | GR antagonist | Moderate | ~0.3 | Phase 2 in AD |
| Firibastat (ABI-HF001) | 11β-HSD1 inhibitor | Moderate | ~0.4 | Phase 2 (NCT04014434) |
| Xanamem | 11β-HSD1 inhibitor | Moderate | ~0.5 | Phase 2 (NCT06125951) |
| Carbenoxolone | 11β-HSD1 inhibitor | Low | ~0.15 | Clinical use (ulcer therapy) |
| RU-28318 | GR agonist | High | ~0.9 | Research use |

Approach 3: GR Modulators (Partial Agonists)

Compound 2 (C2): Selective GR modulator with neuroprotective profile
Tebufone: Non-steroidal GR modulator with improved BBB penetration
Rationale: Achieve transrepression (anti-inflammatory) without transactivation (side effects)

Approach 4: GR Coactivator Modulators

PU91: GR coactivator interaction inhibitor
Rationale: Modulate GR transcriptional activity without affecting ligand binding

Implementation Roadmap

Phase 1 (Months 1-6): Target Validation

Validate GR expression in patient iPSC-derived neurons and post-mortem brain tissue

Test GR modulators in 3xTG-AD and α-synuclein transgenic mice

Establish cortisol and GR translocation biomarkers

Phase 2 (Months 7-18): Lead Optimization

Evaluate blood-brain barrier penetration of GR modulators in non-human primates

Optimize dosing for CNS GR occupancy (PET ligands available)

Assess combination with standard-of-care (AChEIs, levodopa)

Phase 3 (Months 19-36): Clinical Development

Phase 1 safety in healthy volunteers with CNS PK assessments

Phase 2 proof-of-concept in AD (cortisol-positive subgroup) and PD

Biomarker-driven patient enrichment (elevated cortisol, HPA axis dysfunction)

De-risking Path

| Risk | Mitigation |
|------|------------|
| Peripheral GR effects | Use brain-selective compounds or 11β-HSD1 inhibitors |
| Adrenal insufficiency | Careful titration, stress-dose steroids for emergencies |
| Mood effects | Start low, monitor with validated scales |
| Drug-drug interactions | Screen for CYP3A4 interactions with existing neurodegeneration drugs |

Biomarkers for Patient Enrichment

Basal cortisol (morning serum, elevated in ~40% of AD/PD patients)

Dexamethasone suppression test (impaired in HPA axis dysregulation)

Cortisol/DHEA ratio (low DHEA indicates vulnerability)

GR translocation (flow cytometry of peripheral monocytes)

Salivary cortisol AUC (diurnal curve assessment)

Synergistic Combinations

GR Modulator + NRF2 Activator: Address oxidative stress from multiple angles
GR Modulator + Mitochondrial Protectant: Combined mitochondrial protection
GR Modulator + Anti-amyloid: Reduce cortisol-driven Aβ production
GR Modulator + Exercise: Enhance stress resilience and neurogenesis

References

[Sapolsky et al., Glucocorticoids and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[McEwen et al., Stress and the brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Csordas et al., Cortisol in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Foltynie et al., Cortisol in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31187283/)

[De Kloet et al., 11β-HSD1 in brain function (2020)](https://doi.org/10.1016/j.tips.2020.01.002)

[Holsboer, Glucocorticoid receptor function (2022)](https://doi.org/10.1016/j.pharmthera.2022.108189)

[Lupien et al., Cortisol levels during human aging predict hippocampal atrophy (1998)](https://pubmed.ncbi.nlm.nih.gov/9707560/)

[Seckl et al., 11β-Hydroxysteroid dehydrogenase in the brain (2023)](https://doi.org/10.1016/j.yfrne.2023.03.003)

[O'Brien et al., Glucocorticoids and brain atrophy in AD (2024)](https://doi.org/10.1002/ana.26831)

[Holmes et al., 11β-HSD1 as therapeutic target in CNS disorders (2023)](https://doi.org/10.1016/j.tips.2023.04.005)

[Yau et al., Hippocampal glucocorticoid metabolism in aging and AD (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.03.012)

[Hershey et al., 11β-HSD1 activity and cognitive function in aging (2023)](https://doi.org/10.1038/s41386-023-01567-5)

[Actinogen Medical, Xanamem Phase 2 AD Trial (NCT06125951)](https://clinicaltrials.gov/study/NCT06125951)

[Firibastat (ABI-HF001) Phase 2 Trial (NCT04014434)](https://clinicaltrials.gov/study/NCT04014434)

[Glucocorticoid Signaling Pathway in Neurodegeneration](/mechanisms/glucocorticoid-signaling-neurodegeneration)
[Mineralocorticoid Signaling in Neurodegeneration](/mechanisms/mineralocorticoid-signaling-neurodegeneration)
[HPA Axis Dysfunction in Neurodegeneration](/mechanisms/hpa-axis-dysfunction-neurodegeneration)
[Stress Response and Neurodegeneration](/mechanisms/stress-response-neurodegeneration)

📖 View canonical wiki page →

Glucocorticoid Receptor Modulation Therapy for Neurodegeneration

Glucocorticoid Receptor Modulation Therapy for Neurodegeneration

Overview

10-Dimension Rubric Score: 74/100

Disease Coverage

Key Mechanisms

GR Signaling Pathway in Neurodegeneration

1. Cortisol-Mediated Excitotoxicity Prevention

2. Mitochondrial Protection

3. Neuroinflammation Reduction

4. Synaptic Plasticity Preservation

5. Tau Phosphorylation Modulation

Therapeutic Strategy

Approach 1: Selective GR Antagonists

Approach 2: 11β-HSD1 Inhibitors

CNS Penetration Data for GR Modulators

Approach 3: GR Modulators (Partial Agonists)

Approach 4: GR Coactivator Modulators

Implementation Roadmap

Phase 1 (Months 1-6): Target Validation

Phase 2 (Months 7-18): Lead Optimization

Phase 3 (Months 19-36): Clinical Development

De-risking Path

Biomarkers for Patient Enrichment

Synergistic Combinations

References

Related Pages